HH&L Acquisition Co.
HHLA-UN
New York Stock Exchange10.83
USD
+0.08
- -
HH&L Acquisition Co.
HHLA-UN
(New York Stock Exchange)
Recent
price
10.83
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- HH&L Acquisition Co. HH&L Acquisition Co. is a blank check company incorporated in the Cayman Islands whose principal business activity is to pursue a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company focuses on healthcare or healthcare-related companies in Asian markets, particularly the Greater China region, or global healthcare firms with significant growth potential in Greater China or Asia; it does not currently generate revenue from operations or offer products or services beyond its SPAC structure. Headquartered in Hong Kong and founded in 2020, HH&L Acquisition Co. operates globally with an emphasis on Asian target markets and held approximately $414 million in trust proceeds from its initial public offering completed in February 2021. In October 2022, the company entered into a definitive business combination agreement with DiaCarta Ltd., a precision molecular diagnostics firm developing oncology and infectious disease tests, under which HH&L would domesticate to Delaware, acquire DiaCarta in a merger valuing it at a pre-money equity of $460 million, and rename itself DiaCarta Inc., though the transaction terminated mutually in July 2023. Following the failed merger, HH&L Acquisition Co. liquidated in February 2024, redeeming shares from trust at $10.79 per share and ceasing active operations as a SPAC.